AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1538156
Drug: NG-mononmethyl-L-arginine (NMA)
RxNorm normalized name: L-Ng-monomethyl Arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-L-arginine (NMA)
Trial: 3901170
Drug: Diltiazem (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (240 mg)
Trial: 30791824
Drug: Atosiban (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (37.5 mg total dose)
Trial: 26822461
Drug: Supervised group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised group exercise therapy
Trial: 14710804
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise therapy
Trial: 22472585
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges (Lactobacillus reuteri DSM 17938 and ATCC PTA 5289), 2/day for 6 weeks
Trial: 15650887
Drug: EMG activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG activity (agonist and antagonist)
Trial: 12404190
Drug: Sequential combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combined hormone‐replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d for 28 days and 5 mg of medroxyprogesterone acetate during the last 14 days
Trial: 10023944
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (300 mg once daily for 12 weeks)
Trial: 7775624
Drug: Local intraarterial
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local intraarterial infusion of 25 micrograms/h somatostatin
Trial: 7775624
Drug: Systemic control
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic control infusion
Trial: 1651741
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy followed by prophylactic cranial irradiation (PCI) for disease-free patients
Trial: 6130666
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of beta-receptor blockers
Trial: 6130666
Drug: Withdrawal of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal of beta-receptor blockers
Trial: 27552592
Drug: Omega-3 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplements (1,470mg DHA and 147mg EPA daily for 12 weeks)
Trial: 24393602
Drug: Secukinumab Monthly
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab Monthly regimen (Weeks 0, 4, 8)
Trial: 18004129
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 mg/d for 1 week then 200 mg/d for 6 weeks)
Trial: 12468952
Drug: Metoclopramide injection
RxNorm normalized name: metoclopramide Injection
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoclopramide injection (n = 8)
Trial: 380868
Drug: naproxen, 500
RxNorm normalized name: Naproxen, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen, 500 mg/day for 1 week
Trial: 380868
Drug: diclofenac, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac, 100 mg/day for 1 week
Trial: 31101782
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 15 mg/kg/day for 12 months
Trial: 31101782
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 800 mg/day plus Vitamin C 500 mg/day for 12 months
Trial: 23410808
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg monthly intravitreal injection)
Trial: 23410808
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (quarterly intravenous verteporfin coupled with PDT)
Trial: 9492128
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine (first injection)
Trial: 9492128
Drug: Buffered lidocaine
RxNorm normalized name: buffered lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered lidocaine (second injection)
Trial: 3139830
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg) after 30-day therapy
Trial: 31768589
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD (20-μg injection daily for 6 months)
Trial: 31768589
Drug: Weekly TPTD
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly TPTD (56.5-μg injection 1×/week for 6 months)
Trial: 1771090
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg amitriptyline
Trial: 18433307
Drug: MRK adenovirus
RxNorm normalized name: COVID-19 VACCINE ADENOVIRUS-26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRK adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine (3-dose regimen, doses ranging from 3 x 10^6 to 1 x 10^11 viral particles per 1-mL dose)
Trial: 17294878
Drug: Conventional hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional hospital treatment
Trial: 11938802
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal treatment added during prednisone reduction
Trial: 11938802
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment (control group)
Trial: 9104548
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg once daily for 12 weeks
Trial: 8478303
Drug: Dirithromycin 500
RxNorm normalized name: Dirithromycin
DrugBank: Dirithromycin (DB00954)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dirithromycin 500 mg/day orally once daily for 10-14 days
Trial: 8478303
Drug: Erythromycin 1000
RxNorm normalized name: erythromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 1000 mg/day orally four times daily for 10-14 days
Trial: 30051366
Drug: Surgical interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical interventions for rectal cancer
Trial: 23837549
Drug: Constant Current
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant Current (CC) stimulation
Trial: 20581391
Drug: Sirolimus (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (target dose, 2 mg daily)
Trial: 18766092
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of feedback and debriefing
Trial: 10848884
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance tests (ITT) performed during menstrual cycle phases in women
Trial: 10848884
Drug: Insulin tolerance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin tolerance tests (ITT) performed in men
Trial: 2581075
Drug: Timolol 30
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 30 mg
Trial: 2581075
Drug: Timolol 60
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol 60 mg
Trial: 15207544
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium lauryl sulphate (SLS) solution
Trial: 15207544
Drug: Aqueous Cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous Cream BP
Trial: 26133711
Drug: 1 µg/kg of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 µg/kg of DEX
Trial: 16618363
Drug: Prebiotic formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic formula (0.6 g GOS/FOS/100 ml)
Trial: 16618363
Drug: Probiotic formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formula (6.0 x 10^9 cfu Bifidobacterium animalis/100 ml)
Trial: 14744166
Drug: Venlafaxine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 300 mg/day
Trial: 14744166
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to alternate SRI (either paroxetine or venlafaxine) after 4-week tapering phase
Trial: 8276300
Drug: Intraperitoneal radioactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal radioactive therapy followed by thio-TEPA
Trial: 8276300
Drug: 32P treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32P treatment
Trial: 16354890
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives
Trial: 31083170
Drug: Community-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based intervention program (6 sessions, once weekly)
Trial: 23625331
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil (500 mg, 2 capsules per day for 6 weeks)
Trial: 23625331
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules per day for 6 weeks)
Trial: 22212765
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=33) received weekly topic-based reading instructions and five telephone consultations with an audiologist.
Trial: 16418085
Drug: Rapid-sequence intubation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-sequence intubation (RSI) with etomidate (0.3 mg/kg) and succinylcholine (1.5 mg/kg)
Trial: 16418085
Drug: Etomidate-only intubation
RxNorm normalized name: Etomidate
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etomidate-only intubation (EOI) with etomidate (0.3 mg/kg)
Trial: 9001838
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg/benazepril 20 mg
Trial: 11090788
Drug: Low-dose calcium
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcium antagonists
Trial: 24353344
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin E, 400 IU; vitamin C, 500 mg; selenium, 50 μg)
Trial: 30919899
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg daily
Trial: 16208784
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml bupivacaine 0.25% into the margin
Trial: 16208784
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml bupivacaine 0.25% into the cavity
Trial: 16208784
Drug: 5 ml
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml physiological saline into the cavity
Trial: 2837105
Drug: Ethanol (0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.42 g/kg) + marihuana (2.4% THC)
Trial: 2837105
Drug: Ethanol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.85 g/kg) + marihuana (2.4% THC)
Trial: 2837105
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol (0.42 g/kg) + placebo marihuana
Trial: 2837105
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ethanol (0.85 g/kg) + placebo marihuana
Trial: 2837105
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose ethanol (0.42 g/kg) + marihuana (2.4% THC)
Trial: 2837105
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ethanol (0.85 g/kg) + marihuana (2.4% THC)
Trial: 2837105
Drug: Ethanol (0.42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.42 g/kg) + marihuana (0.0004% THC)
Trial: 2837105
Drug: Ethanol (0.85
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.85 g/kg) + marihuana (0.0004% THC)
Trial: 21680702
Drug: SRT501 (micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT501 (micronized resveratrol) 5.0 g daily for 14 days
Trial: 14555261
Drug: Clodronate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate (100 mg im/week) plus calcium (1000 mg) and vitamin D (800 UI)
Trial: 14555261
Drug: Calcium (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1000 mg) and vitamin D (800 UI) alone
Trial: 8741720
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy targeted specifically on the single symptom of their delusional belief(s)
Trial: 1565419
Drug: RGP daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGP daily wear (DWRGP)
Trial: 31685212
Drug: Gemcabene 300
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcabene 300 mg for 4 weeks
Trial: 31685212
Drug: Gemcabene 600
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcabene 600 mg for 4 weeks
Trial: 31685212
Drug: Gemcabene 900
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcabene 900 mg for 4 weeks
Trial: 29767677
Drug: docetaxel +
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel + bavituximab 3 mg/kg
Trial: 23625982
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg prednisolone
Trial: 7557813
Drug: Amitriptyline 30
RxNorm normalized name: amitriptyline 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 30 mg/d
Trial: 7557813
Drug: Flupentixol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 1.5 mg/d
Trial: 7557813
Drug: Clotiazepam 15
RxNorm normalized name: clotiazepam
DrugBank: Clotiazepam (DB01559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotiazepam 15 mg/d
Trial: 7557813
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs compared
Trial: 7235102
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (personal contact added to standard treatment)
Trial: 24908596
Drug: 2% Uncaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% Uncaria tomentosa gel
Trial: 11451620
Drug: Transdermal oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal oestrogen and progesterone (Estraderm TTS 50 and 0.4 mg progesterone vaginal suppository) (n=7)
Trial: 11451620
Drug: Oral oestrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oestrogen and progesterone (2 mg Progynova and 0.4 mg progesterone vaginal suppository) (n=8)
Trial: 8066557
Drug: Inhaled acetaldehyde
RxNorm normalized name: acetaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled acetaldehyde (0.8 mg/ml for 4 minutes)
Trial: 8066557
Drug: Inhaled acetaldehyde
RxNorm normalized name: acetaldehyde
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled acetaldehyde with terfenadine
Trial: 8066557
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo and inhaled saline
Trial: 2848786
Drug: levamisole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levamisole (2.5 mg/kg twice weekly for 2 years or until tumor progression)
Trial: 28539066
Drug: Water-based treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-based treatment
Trial: 28539066
Drug: Land-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based treatment
Trial: 26062180
Drug: Electroacupuncture applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electroacupuncture applied to bilateral Fushe (SP 13) and Shuidao (ST 28); 2 Hz/50 Hz, retaining for 30 min, one treatment
Trial: 24183981
Drug: delNS1‐trivalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delNS1‐trivalent vaccine at 7.0log10 TCID50/subject
Trial: 12379622
Drug: Anti-TNF monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-TNF monoclonal antibody infliximab
Trial: 2651489
Drug: Alprazolam, 0.5-6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam, 0.5-6.0 mg/day
Trial: 2651489
Drug: Adinazolam mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam mesylate, 10-120 mg/day
Trial: 21116
Drug: Fluphenazine/nortriptyline (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluphenazine/nortriptyline (specific antidepressant together with an anxiolytic)
Trial: 21116
Drug: Potassium clorazepate
RxNorm normalized name: potassium clorazepate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium clorazepate (pure anxiolytic)
Trial: 28244612
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea tablets
Trial: 24970794
Drug: Uninterrupted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted oral anticoagulation (UAC)
Trial: 21941091
Drug: ZOSTAVAX (refrigerator-stable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZOSTAVAX (refrigerator-stable formulation), single dose administered within 6 months of expiry
Trial: 21932952
Drug: Subcutaneous unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous unfractionated heparin
Trial: 16520474
Drug: Chloroquine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (150 mg/d for 12 months)
Trial: 15486520
Drug: Milnacipran 75
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran 75 mg daily
Trial: 15486520
Drug: Milnacipran 150
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milnacipran 150 mg daily
Trial: 7799026
Drug: Ciprofloxacin (CIP)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CIP) 750 mg orally twice per day
Trial: 7799026
Drug: Trimethoprim/sulfamethoxazole (TMS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim/sulfamethoxazole (TMS) 160 mg trimethoprim and 800 mg sulfamethoxazole orally twice per day
Trial: 87620
Drug: Apomorphine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine combined with domeperidone (peripheral dopamine receptor blocker)
Trial: 17252567
Drug: PDT (Photodynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDT (Photodynamic Therapy) with MAL (16% methyl aminolevulinate)
Trial: 11843370
Drug: Amnioinfusion (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amnioinfusion (500 mL of normal saline over 30 minutes)
Trial: 9863486
Drug: Erythromycin 40
RxNorm normalized name: erythromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 40 mg after placebo
Trial: 9863486
Drug: Erythromycin 40
RxNorm normalized name: erythromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 40 mg after atropine
Trial: 9863486
Drug: Erythromycin 40
RxNorm normalized name: erythromycin 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 40 mg after sumatriptan
Trial: 9863486
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg after atropine
Trial: 9863486
Drug: Erythromycin 200
RxNorm normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 200 mg after sumatriptan
Trial: 2229750
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy in patients with proximal left anterior descending coronary artery stenosis ≥ 70% and ejection fraction < 0.50
Trial: 2229750
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy in patients with three vessel coronary artery disease and ejection fraction < 0.50
Trial: 31538453
Drug: Chlo‐SITE (chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlo‐SITE (chlorhexidine based local drug delivery) applied in 1 pocket in 2 quadrants after full mouth disinfection